← Ligand Pharmaceuticals Incorporated (LGND) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Ligand Pharmaceuticals Incorporated (LGND)
Pharmaceutical Preparations · market cap $6.0B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
9
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Ligand Pharmaceuticals is a royalty-aggregator and drug-development technology company with ~90 royalty-bearing assets, Captisol technology licensing, and a pipeline that includes lasofoxifene in Phase 3 for osteoporosis. At a $6.3B market cap with 68 employees, Ligand is primarily valued on its royalty stream from marketed products like Kyprolis, Evomela, Filspari, and Vaxneuvance, while carrying net debt of ~$332M against $115M cash.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| irbesartan | Phase 2 | Hypertension |
| LGD-6972-5 mg | Phase 2 | Type 2 Diabetes Mellitus |
| MB07803 | Phase 2 | Type 2 Diabetes Mellitus |
| MB07133 300mg/m2/day | Phase 2 | Hepatocellular Carcinoma |
| bexarotene | Phase 2 | Breast Cancer |
| lasofoxifene | Phase 3 | Osteoporosis |
| denileukin diftitox | Phase 2 | Drug/Agent Toxicity by Tissue/Organ |
| PS433540 | Phase 2 | Hypertension |
| Aplindore | Phase 2 | Early Stage Parkinson's Disease |
Price & technical context
3-month
-5.3%
6-month
+51.7%
12-month
+70.9%
52-wk range
$177.73–$322.61
vs 50-day MA
+3.8%
vs 200-day MA
+25.5%
Realized vol
36.3%
Max drawdown
-25.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LGND (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.